EHA 2019 | MRD detection with NGS for AML: a new era of diagnostics

Torsten Haferlach

Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, sheds light on a potential of a new era in diagnostics with the use of next-generation sequencing (NGS) for detecting measurable residual disease (MRD) status. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video